Literature DB >> 15118837

In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein.

N Harry Hendrikse1, Folkert Kuipers, Coby Meijer, Rick Havinga, Charles M A Bijleveld, Winette T A van der Graaf, Willem Vaalburg, Elisabeth G E de Vries.   

Abstract

Multidrug resistance associated proteins (MRPs) and P-glycoprotein (P-gp) are involved in hepatobiliary transport of various compounds. Our aim was (1) to define transporter specificity of the cholescintigraphic agents 99mTc-HIDA and 99mTc-MIBI, which are used clinically for myocardial perfusion measurements; and (2) to deduce MRP and P-gp functions in vivo from hepatic 99mTc kinetics. Accumulation of radioactivity was measured in the human tumor cell lines GLC4, GLC4/ADR150x (MRP1-overexpressing/P-gp-negative) and GLC4/P-gp (P-gp-overexpressing). Bile secretion was quantified in untreated and in glutathione-depleted control and MRP2-deficient (GY/TR-) rats. Hepatobiliary transport was measured using a gamma camera in both types of rats. 99mTc-HIDA accumulated 5.8-fold less in GLC4/ADR150x calls than in GLC4 or GLC4/P-gp cells. In GLC4/ADR150x, the cellular 99mTc-HIDA content was increased 3.4-fold by the MRP1,2 inhibitor MK571 (50 microM), while MK571 had no measurable effect in GLC4 and GLC4/P-gp cells. 99mTc-MIBI accumulated less in GLC4/P-gp and GLC4/ADR150x cells than in GLC4 cells. Bile secretion of 99mTc-HIDA was impaired in GY/TR- compared to control rats and not affected by glutathione depletion in GY/TR- rats. Hepatic secretion of 99mTc-HIDA was slower in GY/TR- (t1/2 40 min) than in control rats (t1/2 7 min). Bile secretion of 99mTc-MIBI was similar in both rat strains and impaired by glutathione depletion in control rats only, indicating compensatory activity of additional transporter(s) in GY/TR- rats. 99mTc-HIDA is transported only by MRP1,2 only, while 99mTc-MIBI is transported by P-gp and MRP1,2. The results indicate that hepatic P-gp and MRP1,2 function can be assessed in vivo by sequential use of both radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118837     DOI: 10.1007/s00280-004-0793-2

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

2.  Hepatobiliary function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of severity of steatosis in a rat model.

Authors:  Reeta L Veteläinen; Roelof J Bennink; Kora de Bruin; Arlène van Vliet; Thomas M van Gulik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10       Impact factor: 9.236

3.  Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes.

Authors:  Brandon Swift; Wei Yue; Kim L R Brouwer
Journal:  Pharm Res       Date:  2010-07-22       Impact factor: 4.200

Review 4.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

5.  Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.

Authors:  Giulia Ghibellini; Elaine M Leslie; Gary M Pollack; Kim L R Brouwer
Journal:  Pharm Res       Date:  2008-05-30       Impact factor: 4.200

6.  Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs.

Authors:  N D Pfeifer; S L Goss; B Swift; G Ghibellini; M Ivanovic; W D Heizer; L M Gangarosa; K L R Brouwer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-02

7.  The Herbal Constituents in An-Gong-Niu-Huang Wan (AGNH) Protect against Cinnabar- and Realgar-Induced Hepatorenal Toxicity and Accumulations of Mercury and Arsenic in Mice.

Authors:  Songsong Wang; Xiao Xiao; Ao Li; Peng Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-01       Impact factor: 2.629

8.  Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.

Authors:  Izna Ali; Jason R Slizgi; Josh D Kaullen; Marija Ivanovic; Mikko Niemi; Paul W Stewart; Alfred S Barritt; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2017-12-22       Impact factor: 6.875

Review 9.  Liver Functional Volumetry by Tc-99m Mebrofenin Hepatobiliary Scintigraphy before Major Liver Resection: A Game Changer.

Authors:  Manoj Gupta; Partha Sarathi Choudhury; Shivendra Singh; Dibyamohan Hazarika
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec

10.  Imaging of hepatic drug transporters with [131I]6-β-iodomethyl-19-norcholesterol.

Authors:  Masato Kobayashi; Kodai Nishi; Asuka Mizutani; Tsuzumi Hokama; Miki Matsue; Tetsuya Tsujikawa; Takeo Nakanishi; Ryuichi Nishii; Ikumi Tamai; Keiichi Kawai
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.